Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors. Sanchez-Bayona R, Oliveira M. Ann Oncol 2024;35:689-691.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sanchez-Bayona R, Oliveira M. Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors. Ann Oncol 2024;35:689-691.
PMID: 39048261